|
|
|
09148
|
|
|
P.I.:
|
Robert Chen, MD
|
|
|
Title:
|
SGN-35-008 An Open Label Clinical Pharmacology Study of Bretnuximab Vedotin (SGN-35) in Patients with CD-30 Positive Hematologic Malignancies: CYP3A
|
| | |
|
|
09129
|
|
|
P.I.:
|
Vincent Chung, MD
|
|
|
Title:
|
A Phase IA, Multicenter, Open-Label Dose Escalation Study of BKM120, Administered Orally in Adult Patients with Advanced Solid Malignancies
|
|
|
09128
|
|
|
P.I.:
|
Mihaela Cristea, MD
|
|
|
Title:
|
A Phase Ib, Parallel Arm, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination with Two Different Chemotherapy Regimens in Women with Platinum Resistant or Platinum Sensitive Ovarian Cancer
|
| | |
|
|
09082
|
|
|
P.I.:
|
Karen Reckamp, MD
|
|
|
Title:
|
Phase 1b Open label, Dose Escalation Study of AMG 655 in Combination with AMG 479 in Subjects with Advanced, Refractory Solid Tumors
|
| | |
|
|
09079
|
|
|
P.I.:
|
George Somlo, MD
|
|
|
Title:
|
A Phase Ib Multiple Ascending Dose Study of BMS-833923 (XL 139) Alone or in Combination with Lenalidomide (Revlimid) Plus Dexamethasone or in Combination with Bortezomib (Velcade) in Subjects with Relapsed or Refractory Multiple Myeloma, BMS CA 194003
|
| | |
|